

Dog/Canine Brucella Ab IgG ELISA Kit

Catalog Number BG-CAN10403

Enzyme immunoassays (microtiter strips) for the qualitative and quantitative determination of IgG antibodies against Brucella in Canine serum and plasma.

Intended for research use only

1. INTENDED USE

Enzyme immunoassays (micotiter strips) for the qualitative and quantitative determination of IgG antibodies against Brucella in Canine serum and plasma.

2. SUMMARY AND EXPLANATION

Brucellosis is an infectious disease caused by small ellipsoid, gram-negative bacteria. There are four different germs: *Br. abortus*, *Br. melitensis*, *Br. suis* and *Br. canis*. People are infected by contact with infected animals or by swallowing meat or unpasteurized milk from infected animals. Infected Canines are not contagious. The incubation period may take one to three weeks, in some cases two months. *Br. abortus* and *Br. melitensis* cause Bang's Disease, and rarely the Malta Fever. Typical symptoms for Bang's Disease are periodically occurring fever, splenomegaly and swelling of lymph nodes. In some cases an inflammation of different joints and organs occurs. Malta Fever is caused by the epidemic type of brucellosis. Infection almost always leads to a manifest illness. Brucella also can cause Brucella Hepatitis. In addition, it is possible that there is a link between an infection with Brucella and the outbreak of multiple sclerosis.

During an antibiotic therapy or a chronic infection, the detection of *Brucella spec.* in blood, urine, cerebrospinal fluid, sputum or other body fluids may be negative. Serological methods like agglutination, complement fixation reaction, Brucella Coombs test and ELISA are good alternatives. To monitor the status of infection antibodies can serve as a usual indication. During the first days, IgM is the only immunoglobulin appearing. As the disease progresses, IgM recedes quantitatively and IgG becomes predominant. In chronic brucellosis, IgG may be produced for extended periods.

3. TEST PRINCIPLE

Solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. The wells are coated with antigen. Specific antibodies of the sample binding to the antigen coated wells are detected by a secondary enzyme conjugated antibody (E-Ab) specific for Canine IgG. After the substrate reaction the intensity of the color developed is proportional to the amount of IgG-specific antibodies detected. Results of samples can be determined directly using the standard curve.

4. WARNINGS AND PRECAUTIONS

1. For *in-vitro diagnostic* use only. For professional use only.
2. Before starting the assay, read the instructions completely and carefully. Use the valid version of the package insert provided with the kit. Be sure that everything is understood.
3. In case of severe damage of the kit package please contact IBL or your supplier in written form, latest one week after receiving the kit. Do not use damaged components in test runs, but keep safe for complaint related issues.
4. Obey lot number and expiry date. Do not mix reagents of different lots. Do not use expired reagents.
5. Follow good laboratory practice and safety guidelines. Wear lab coats, disposable latex gloves and protective glasses where necessary.
6. Reagents of this kit containing hazardous material may cause eye and skin irritations. See MATERIALS SUPPLIED and labels for details.
7. Chemicals and prepared or used reagents have to be treated as hazardous waste according to national biohazard and safety guidelines or regulations.
8. The cleaning staff should be guided by the professionals regarding potential hazards and handling.
9. Avoid contact with Stop solution. It may cause skin irritations and burns.
10. Some reagents contain sodium azide (NaN₃) as preservatives. In case of contact with eyes or skin, flush immediately with water. NaN₃ may react with lead and copper plumbing to form explosive metal azides. When disposing reagents, flush with a large volume of water to avoid azide build-up.
11. All reagents of this kit containing Canine serum or plasma have been tested and were found negative for anti-HIV I/II, HBsAg and anti-HCV. However, a presence of these or other infectious agents cannot be excluded absolutely. For this reason reagents should be treated as potential biohazards in use and for disposal.

5. STORAGE AND STABILITY

The kit is shipped at ambient temperature and should be stored at 2-8 °C. Keep away from heat or direct sunlight. The storage and stability of specimens and prepared reagents is stated in the corresponding chapters.

The unopened reagents are stable until the expiry date indicated. The Kit is stable up to 3 months after the first opening when the Microtiterplate is packed in a tightly closed bag, the bottles are closed with their screw caps and the kit is stored at 2-8°C.

6. SPECIMEN COLLECTION AND STORAGE

Serum, Plasma (EDTA, Heparin)

The usual precautions for venipuncture should be observed. It is important to preserve the chemical integrity of a blood specimen from the moment it is collected until it is assayed. Do not use grossly hemolytic, icteric or grossly lipemic specimens. Samples appearing turbid should be centrifuged before testing to remove any particulate material.

| | | | |
|------------|--------|----------|---|
| Storage: | 2-8 °C | -20 °C | Keep away from heat or direct sunlight. Avoid repeated freeze-thaw cycles. |
| Stability: | 7 days | > 7 days | |

7. MATERIALS SUPPLIED

| Quantity | Symbol | Component |
|--------------|----------------------------|--|
| 1 x 12 x 8 | MTP | Microtiter Plate Break apart strips. Coated with specific antigen. |
| 1 x 15 mL | ENZCONJ IgG | Enzyme Conjugate IgG Red colored. Ready to use. Contains: anti-Canine IgG, conjugated to peroxidase (rabbit), protein-containing buffer, 0.01 % Methylisothiazolinone, 0.01 % Bromonitrodioxane and 5 mg/L ProClin. |
| 1 x 4 x 2 mL | CAL A-D | Standard A-D 1; 10; 40; 150 U/mL. Ready to use. Standard A = Negative Control Standard C = Weakly Positive Control Standard B = Cut-Off Control Standard D = Positive Control Contains: IgG antibodies against Brucella, PBS, 0.01% Methylisothiazolinone and 0.01 % Bromonitrodioxane. |
| 1 x 60 mL | DILBUF | Diluent Buffer Ready to use. Contains: PBS Buffer, BSA, < 0.1 % NaN ₃ . |
| 1 x 60 mL | WASHBUF CONC | Wash Buffer, Concentrate (10x) Contains: PBS Buffer, Tween 20. |
| 1 x 15 mL | TMB SUBS | TMB Substrate Solution Ready to use. Contains: TMB. |
| 1 x 15 mL | TMB STOP | TMB Stop Solution Ready to use. 0.5 M H ₂ SO ₄ . |
| 2 x | FOIL | Adhesive Foil For covering of Microtiter Plate during incubation. |
| 1 x | BAG | Plastic Bag Resealable. For dry storage of non-used strips. |

8. MATERIALS REQUIRED BUT NOT SUPPLIED


1. Micropipettes (Multipette Eppendorf or similar devices, < 3 % CV). Volumes: 5; 50; 100; 500 µL
2. Calibrated measures
3. Tubes (1 mL) for sample dilution
4. 8-Channel Micropipettor with reagent reservoirs
5. Wash bottle, automated or semi-automated microtiter plate washing system
6. Microtiter plate reader capable of reading absorbance at 450 nm (reference wavelength 600-650 nm)
7. Bidistilled or deionised water
8. Paper towels, pipette tips and timer

9. PROCEDURE NOTES

1. Any improper handling of samples or modification of the test procedure may influence the results. The indicated pipetting volumes, incubation times, temperatures and pretreatment steps have to be performed strictly according to the instructions. Use calibrated pipettes and devices only.
2. Once the test has been started, all steps should be completed without interruption. Make sure that required reagents, materials and devices are prepared ready at the appropriate time. Allow all reagents and specimens to reach room temperature (18-25 °C) and gently swirl each vial of liquid reagent and sample before use. Mix reagents without foaming.
3. Avoid contamination of reagents, pipettes and wells/tubes. Use new disposable plastic pipette tips for each component and specimen. Do not interchange caps. Always cap not used vials. Do not reuse wells/tubes or reagents.
4. Use a pipetting scheme to verify an appropriate plate layout.
5. Incubation time affects results. All wells should be handled in the same order and time sequences. It is recommended to use an 8-channel Micropipettor for pipetting of solutions in all wells.
6. Microtiter plate washing is important. Improperly washed wells will give erroneous results. It is recommended to use a multichannel pipette or an automatic microtiter plate washing system. Do not allow the wells to dry between incubations. Do not scratch coated wells during rinsing and aspiration. Rinse and fill all reagents with care. While rinsing, check that all wells are filled precisely with Wash Buffer, and that there are no residues in the wells.
7. Humidity affects the coated wells/tubes. Do not open the pouch until it reaches room temperature. Unused wells/tubes should be returned immediately to the resealed pouch including the desiccant.

10. PRE-TEST SETUP INSTRUCTIONS

10.1. Preparation of Components

| | |
|---|---|
|  | The contents of the kit for 96 determinations can be divided into 3 separate runs. The volumes stated below are for one run with 4 strips (32 determinations). |
|---|---|

| Dilute / dissolve | Component | | Diluent | Relation | Remarks | Storage | Stability |
|-------------------|----------------------------|--------|---------------|----------|--|---------|-----------|
| 20 mL | WASHBUF CONC | 180 mL | bidist. water | 1:10 | Warm up at 37°C to dissolve crystals, if necessary. Mix vigorously. | 2-8 °C | 8 weeks |

10.2. Dilution of Samples

| Sample | to be diluted | with | Relation | Remarks |
|----------------|---------------|---------------|----------|----------------------------------|
| Serum / Plasma | generally | DILBUF | 1:101 | e.g. 5 µL + 500 µL DILBUF |

Samples containing concentrations higher than the highest standard have to be diluted further.

11. TEST PROCEDURE

| | |
|-----|--|
| 1. | Pipette 100 µL of each Standard and diluted sample into the respective wells of the Microtiter Plate. In the qualitative test only Standard B is used. |
| 2. | Cover plate with adhesive foil. Incubate 60 min at 18-25 °C. |
| 3. | Remove adhesive foil. Discard incubation solution. Wash plate 3 x with 300 µL of diluted Wash Buffer . Remove excess solution by tapping the inverted plate on a paper towel. |
| 4. | Pipette 100 µL of Enzyme Conjugate into each well. |
| 5. | Cover plate with new adhesive foil. Incubate 30 min at 18-25 °C. |
| 6. | Remove adhesive foil. Discard incubation solution. Wash plate 3 x with 300 µL of diluted Wash Buffer . Remove excess solution by tapping the inverted plate on a paper towel. |
| 7. | For adding of Substrate and Stop Solution use, if available, an 8-channel Micropipettor. Pipetting should be carried out in the same time intervals for Substrate and Stop Solution. Use positive displacement and avoid formation of air bubbles. |
| 8. | Pipette 100 µL of TMB Substrate Solution into each well. |
| 9. | Incubate 20 min at 18-25 °C in the dark (without adhesive foil). |
| 10. | Stop the substrate reaction by adding 100 µL of TMB Stop Solution into each well. Briefly mix contents by gently shaking the plate. Color changes from blue to yellow. |
| 11. | Measure optical density with a photometer at 450 nm (Reference-wavelength: 600-650 nm) within 60 min after pipetting of the Stop Solution. |

12. QUALITY CONTROL

The test results are only valid if the test has been performed following the instructions. Moreover the user must strictly adhere to the rules of GLP (Good Laboratory Practice) or comparable standards /laws. User and/or laboratory must have a validated system to get diagnosis according to GLP. All standards/controls must be found within the acceptable ranges as stated on the QC Certificate. If the criteria are not met, the run is not valid and should be repeated. Each laboratory should use known samples as further controls. It is recommended to participate at appropriate quality assessment trials.

In case of any deviation the following technical issues should be proven: Expiration dates of (prepared) reagents, storage conditions, pipettes, devices, incubation conditions and washing methods.

13. CALCULATION OF RESULTS

The evaluation of the test can be performed either quantitatively or qualitatively.

13.1. Qualitative Evaluation

The Cut-off value is given by the optical density (OD) of the Standard B (Cut-off standard). The Cut-off index (COI) is calculated from the mean optical densities of the sample and Cut-off value. If the optical density of the sample is within a range of 20% around the Cut-off value (grey zone), the sample has to be considered as borderline. Samples with higher ODs are positive, samples with lower ODs are negative.

For a quantification, the Cut-off index (COI) of the samples can be formed as follows:

$$COI = \frac{OD \text{ Sample}}{OD \text{ Standard B}}$$

13.2. Quantitative Evaluation

The obtained OD of the standards (y-axis, linear) are plotted against their concentration (x-axis, logarithmic) either on semi-logarithmic graph paper or using an automated method. A good fit is provided with cubic spline or point-to-point curve, because these methods give the highest accuracy in the data calculation.

For the calculation of the standard curve, apply each signal of the standards (one obvious outlier of duplicates might be omitted and the more plausible single value might be used).

The concentration of the samples can be read directly from the standard curve.


The initial dilution has been taken into consideration when reading the results from the graph. Results of samples of higher predilution have to be multiplied with the dilution factor.

Samples showing concentrations above the highest standard have to be diluted as described in PRE-TEST SETUP INSTRUCTIONS and reassayed.

Typical Calibration Curve

(Example. Do not use for calculation!)

| Standard | U/mL | OD _{Mean} |
|----------|------|--------------------|
| A | 1 | 0.057 |
| B | 10 | 0.517 |
| C | 40 | 1.049 |
| D | 150 | 2.021 |



14. INTERPRETATION OF RESULTS

| Method | Range | Interpretation |
|-------------------------------------|-------------|----------------|
| Quantitative (Standard curve) | < 8 U/mL | negative |
| | 8 – 12 U/mL | equivocal |
| | > 12 U/mL | positive |
| Qualitative (Cut-off Index, COI) | < 0.8 | negative |
| | 0.8 – 1.2 | equivocal |
| | > 1.2 | positive |

The results themselves should not be the only reason for any therapeutical consequences. They have to be correlated to other clinical observations and diagnostic tests.

15. EXPECTED VALUES

In an in-house study, apparently healthy subjects showed the following results:

| Ig Isotype | n | Interpretation | | |
|------------|----|----------------|-----------|----------|
| | | positive | equivocal | negative |
| IgG | 88 | 0 % | 0 % | 100 % |

16. LIMITATIONS OF THE PROCEDURE

Specimen collection and storage have a significant effect on the test results. See SPECIMEN COLLECTION AND STORAGE for details.

Azide and thimerosal at concentrations > 0.1 % interfere in this assay and may lead to false results.

The following blood components do not have a significant effect (+/- 20% of expected) on the test results up to the below stated concentrations:

| | |
|--------------|-----------|
| Hemoglobin | 8.0 mg/mL |
| Bilirubin | 0.3 mg/mL |
| Triglyceride | 5.0 mg/mL |

17. PERFORMANCE

| | |
|------------------------|---|
| Intra-Assay Precision | 8.7 % |
| Inter-Assay Precision | 7.9 % |
| Inter-Lot Precision | 4.1 – 8.8 % |
| Analytical Sensitivity | 1.11 U/mL |
| Recovery | 82 – 96 % |
| Linearity | 80 – 115 % |
| Cross Reactivity | No cross-reactivities were found to: Bordetella pertussis |
| Clinical specificity | 100 % |
| Clinical sensitivity | 100 % |

18. PRODUCT LITERATURE REFERENCES

1. Abdollahi A, Morteza A, Khalilzadeh O, Rasoulinejad M, Brucellosis serology in HIV infected patients, *J Infect Dis* 14(10): 904-6 (2010)
2. Araj GF, Evaluation of ELISA in the diagnosis of acute and chronic brucellosis in Canine beings, *J Hyg Camb* 97: 457-469 (1986)
3. Aminzadeh Z, Farrokhi B, Zanjani HA, Aliyari F, Baiati Z, Navaei F, Mirzaei J, Screening of household members and contacts of patients with acute brucellosis to detect unrecognized cases, *J Inf Dis Immun* 2(3): 41-43 (2010)
4. Cakan G, Bezirci FB, Kacka A, Cesur S, Aksaray S, Tezeren D, Saka D, Ahmed K, Assessment of Diagnostic Enzyme-Linked Immunosorbent Assay Kit and Serological Markers in Canine Brucellosis, *Jpn J Infect Dis* 61: 366-70 (2008)
5. Goldstein J, Blay R, Frasc C, Beining PR, Betts M, Hernandez D, Hoffman T, Golding B, Immunogenicity of Brucella abortus and lipopolysaccharide derived from Brucella abortus, in mouse and Canine: potential as carriers in development of vaccine for AIDS, p. 227-234, In MZ Atassi (ed.), *Advances in experimental medicine and biology*, Plenum Publishing Corp., New York (1991)
6. Heydari F, Mozaffari NA, Tukmechi A, Comparison of Standard Seroagglutination Tests and ELISA for Diagnosis of Brucellosis in West Azerbaijan Province, Iran, *Res J of Biological Sciences* 3(12): 1460-62 (2008)
7. Karsen H, Tekin Koruk S, Duygu F, Yapici K, Kati M, Review of 17 cases of neurobrucellosis: clinical manifestations, diagnosis, and management, *Arch Iran Med* 15(8): 491-4 (2012)
8. MacMillan AP, Greiser-Wilke I, Moennig V, Mathias LA, A competition enzyme immunoassay for brucellosis diagnosis, *Dtsch Tierarztl Wochenschr* 97(2): 83-85 (1990)
9. Mailles A, Rautureau S, Le Horgne J, Poinet-Leroux B, D Arnoux C, Denetiere G, Faure M, Lavigne J, Bru J, Garin-Bastuji B, Re-emergence of brucellosis in cattle in France and risk for Canine health, *Euro Surveill.* 17(30) (2012)
10. Murrell TG, Matthews BJ, Multiple sclerosis--one manifestation of neurobrucellosis?, *Med Hypotheses* 33(1): 43-48 (1990)
11. Otlu S, Sahin M, Atabay HI, Unver A, Serological Investigations of Brucellosis in Cattle, Farmers and Veterinarians in the Kars District of Turkey, *Acta Vet BRNO* 77: 117-21 (2008)
12. Rajai M, Naghili B, Pourhassan A, Comparison of ELISA and STA tests in diagnosis of Brucellosis, *Iran J Clin Infect Dis* 1(3): 145-47 (2006)
13. Revich B, Tokarevich N, Parkinson AJ, Climate change and zoonotic infections in the Russian Arctic, *Int J Circumpolar Health* 71: 1-8 (2012)
14. Smith MC, Exclusion of infectious diseases from sheep and goat farms, *Vet Clin North Am Food Anim Pract* 6: 705-20 (1990)
15. Vakili Z, Momen Heravi M, Sharif AR, Masoomi M, Sensitivity and specificity of ELISA test in diagnosis of brucellosis, *Kowsar Medical Journal* 15(2): 95-98 (2010)
16. Young EJ, Serologic diagnosis of Canine brucellosis: analysis of 214 cases by agglutination tests and review of the literature, *Rev Infect Dis* 13: 359-72 (1991)

Manufactured and Distributed by:

Novatein Biosciences

310 W Cummings Park,

Woburn, MA 01801, USA

Phone: (617) 238-1396

Fax: (617) 380-0053

Toll Free: (888) 856-2858

<http://www.novateinbio.com/>

Email: Info@novateinbio.com